ISAR-DESIRE 3 did not show that paclitaxel-eluting balloon may be useful for treating restenosis of a sirolimus–eluting stent. This study tests the safety and efficacy of a paclitaxel-eluting balloon versus a paclitaxel-eluting stent in cases of in-stent drug-eluting restenosis. We included 220 patients with in-stent restenosis of a drug-eluting stent ball randomized at a 1:1...
Asymmetrical expansion of the stent produces an uneven neointimal growth and increases the risk of thrombosis. The study was divided into two parts: the first one aimed at comparing, in the acute phase and the medium term, the result of provisional bifurcation stenting technique with sirolimus-eluting stent vs everolimus-eluting stent (both guided by IVUS); the...
Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used in more than 50,000 patients, is a sirolimus-eluting device with a bio-degradable polymer. Animal studies showed rapid and complete endothelialization. The study included 20 patients with stable angina randomized on a 1:1 ratio to receive, in the same...
This balloon expandable stent is combined with a guide 0.014 in its distal part. The platform is made of cobalt chrome and the polymer is bio-degradable. 30 patients were included prospectively and there was angiographic follow-up with IVUS and OCT after 6 months. The reference vessel diameter was 2.69 mm ± 0.48, with a length...
The study aims to evaluate clinical, angiographic and IVUS results of the new platinum chromium everolimus stent. The new design of the device has additional proximal connectors to enhance the longitudinal strength where distortion is more common. Included were 100 patients with de novo coronary lesions and a reference diameter of 2.5 to 4 mm...
This new stent is a sirolimus-eluting low-profile cobalt chrome platform (80 µm) with a rapid resorption polymer (3 months). Theoretically, it presents less risk of inflammation of the vessel due to the kinetics of drug elution and polymer degradation. The objective of this study was to test the safety and efficacy of the new device....
This new device is a stainless steel platform of 120 µm thick with a sirolimus-eluting bio-absorbable polymer. It has two separate parts: a larger diameter proximal part and a smaller diameter distal part connected by two 1.2 mm structures. The objective of this study was to test (first in man) the device in bifurcations. We...
This non-inferiority design study compared the sirolimus-eluting stent with biodegradable polymer versus everolimus-eluting stent with permanent polymer in de novo coronary lesions. The primary endpoint was late lumen loss at nine months. We Included 440 patients with stable coronary lesions randomized 2:1 to receive the new sirolimus eluting stent with biodegradable polymer versus everolimus eluting...
The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good results in this context, but no direct comparisons available of pharmacological balloonsversus second-generation DES.This prospective, multicenter randomized 189 patients with in-stent restenosis of conventional stents receiving pharmacological balloon or everolimusDES.The primary endpoint was angiographicat 9 months spotting a...
Few studies have compared head to head the 2nd generation drug eluting stents. This study randomized 1:1 3671 patients to receive a biolimus eluting stent with biodegradable polymer (1880 patients) versus zotarolimus-eluting stent with biocompatible polymer (1791 patients). No significant differences were observed between the two groups in terms of clinical or angiographic features. Approximately...